IPO

Explore the landscape of IPO in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on IPO to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis
CompanyDrug

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis

Ascletis Pharma Inc. (HKG: 1672) announced positive results from a randomized, double‑blind, placebo‑controlled 28‑day proof‑of‑concept clinical trial of ASC50 in U.S. patients with mild‑to‑moderate plaque psoriasis. ASC50 is an in‑house…

CSPC's SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

CSPC’s SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

Novo Nordisk Licenses Hengrui's HRS‑1596 in Up to USD 2.6 Billion Global Deal – Once‑Weekly Oral Candidate for Obesity and Type 2 Diabetes

Novo Nordisk Licenses Hengrui’s HRS‑1596 in Up to USD 2.6 Billion Global Deal – Once‑Weekly Oral Candidate for Obesity and Type 2 Diabetes

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Shandong Branden Medical Devices Files for IPO on STAR Board to Raise RMB 760M

CompanyDeals

Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D

CompanyDeals

Sichuan Biokin Pharma Plans IPO on STAR Board to Raise RMB 1.422 Billion

CompanyDeals

Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion

CompanyDeals

Aier Eye Hospital Group Plans IPO on ChiNext Board

CompanyDeals

Suzhou Novoprotein Lists on Shanghai’s STAR Market for R&D Expansion

CompanyDeals

Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions

CompanyDeals

InnoCare Pharma’s IPO Raises $411M for Drug R&D and Platform Upgrade

Show More